Test aims to help clinicians decide whether patients who test negative will need further biopsy procedures. FDA approved Gen-Probe’s Progensa® PCA3 (Prostate Cancer gene 3) assay, which the firm ...

Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. Background: Active ...

Data comparing tests designed to predict the likelihood of finding significant prostate cancer on biopsy are limited. A comparison of two such tests—the Prostate Health Index (phi) and prostate cancer ...

DiagnoCure reported positive data at the American Urological Association (AUA) meeting from a multicenter study to independently validate the Progensa PCA3 assay for the detection of prostate cancer ...

March 30, 2007 — A new test for prostate cancer, which measures levels of the prostate cancer gene 3 (PCA3) in urine, may be useful in diagnosing prostate cancer in men who have elevated serum levels ...

February 7, 2008 — Novel urine biomarker tests can detect prostate cancer more accurately than other currently available screening methods, researchers report. Results of a study published in the ...

see Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? The unacceptably high rate of false-positive ...

The clinical study leading to FDA approval of the PCA3 test in February of 2012 was a multicenter study from 14 clinical sites. The study included 466 men aged 50 years or older who had at least one ...

WASHINGTON (Reuters) - A urine test can help doctors better spot prostate cancer than either the current blood test or a rectal exam alone, U.S. researchers reported on Tuesday. They said Gen-Probe's ...